Matthias Wirth
Overview
Explore the profile of Matthias Wirth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tapia Contreras C, Falke J, Seifert D, Schneider C, Krauss L, Fang X, et al.
Mol Oncol
. 2024 Sep;
19(2):295-310.
PMID: 39253995
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients....
2.
Schneider C, Hilbert J, Genevaux F, Hofer S, Krauss L, Schicktanz F, et al.
Adv Sci (Weinh)
. 2024 Jun;
11(31):e2307695.
PMID: 38885414
Cancer cells must develop strategies to adapt to the dynamically changing stresses caused by intrinsic or extrinsic processes, or therapeutic agents. Metabolic adaptability is crucial to mitigate such challenges. Considering...
3.
Wirth M, Schneider G
Cancer Res
. 2024 Jun;
84(11):1739-1741.
PMID: 38831749
Epithelial-to-mesenchymal transition (EMT) is a classical cellular plasticity process induced by various cell-intrinsic and -extrinsic triggers. Although prominent factors, such as TGFβ, mediate EMT via well-characterized pathways, alternative avenues are...
4.
Mazur P, Herner A, Mello S, Wirth M, Hausmann S, Sanchez-Rivera F, et al.
Nat Med
. 2024 May;
30(7):2090.
PMID: 38816611
No abstract available.
5.
Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauss L, Schneeweis C, et al.
Bioorg Chem
. 2024 Mar;
146:107248.
PMID: 38458892
No abstract available.
6.
Donig J, Mende H, Davila Gallesio J, Wagner K, Hotz P, Schunck K, et al.
Nat Commun
. 2023 Dec;
14(1):8121.
PMID: 38065954
Ribosome biogenesis is a multi-step process, in which a network of trans-acting factors ensures the coordinated assembly of pre-ribosomal particles in order to generate functional ribosomes. Ribosome biogenesis is tightly...
7.
Wirth M, Brenner W, Kramer O
Signal Transduct Target Ther
. 2023 Aug;
8(1):325.
PMID: 37652938
No abstract available.
8.
Ashry R, Mustafa A, Hausmann K, Linnebacher M, Strand S, Sippl W, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509312
Epigenetic modifiers of the histone deacetylase (HDAC) family are often dysregulated in cancer cells. Experiments with small molecule HDAC inhibitors (HDACi) have proven that HDACs are a vulnerability of transformed...
9.
Zhang L, Wirth M, Patra U, Stroh J, Isaakidis K, Rieger L, et al.
EMBO Mol Med
. 2023 Jul;
15(9):e16431.
PMID: 37485814
The DNA damage response (DDR) acts as a barrier to malignant transformation and is often impaired during tumorigenesis. Exploiting the impaired DDR can be a promising therapeutic strategy; however, the...
10.
Schneeweis C, Diersch S, Hassan Z, Krauss L, Schneider C, Lucarelli D, et al.
Cell Mol Life Sci
. 2022 Dec;
80(1):12.
PMID: 36534167
Targeting KRAS downstream signaling remains an important therapeutic approach in pancreatic cancer. We used primary pancreatic ductal epithelial cells and mouse models allowing the conditional expression of oncogenic Kras, to...